The past few years have witnessed considerable advances in the field of cardiovascular pharmacogenomics, not least as a result of genome-wide surveys. We here briefly review recent advances supporting the value of genetic information in the treatment of patients with betablockers, statins and warfarin. Although definitive proof that genotyping can change outcomes of patients with cardiovascular diseases await randomised trials, personalised cardiovascular pharmacotherapy is on the verge of entering clinical practice.